Universal Health Services vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (77 vs 81)
Universal Health Services logo

Universal Health Services

LeaderHealthcare Tech

Hospital & Behavioral Health

Universal Health Services (UHS) reported ~$15.7B revenue in FY2024. Leading hospital and behavioral health facility operator with 350+ acute care and psychiatric hospitals in the U.S. HQ: King of Prussia, PA.

AI VisibilityBeta
Overall Score
B77
Category Rank
#49 of 596
AI Consensus
84%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
80
Gemini
81

About

Universal Health Services, Inc. is one of the largest hospital and behavioral health facility operators in the United States, providing acute care hospital services, inpatient and outpatient behavioral health services, and specialized medical services. Founded in 1978 by Alan Miller, UHS operates approximately 350+ facilities — including general hospitals, surgical hospitals, freestanding emergency departments, and over 200 behavioral health centers treating mental illness and substance abuse disorders. The company operates across 37 states, Washington, D.C., and the United Kingdom.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

77
Overall Score
81
#49
Category Rank
#17
84
AI Consensus
71
stable
Trend
stable
78
ChatGPT
80
80
Perplexity
75
81
Gemini
77
75
Claude
86
76
Grok
85

Key Details

Category
Hospital & Behavioral Health
General
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Universal Health Services
Hospital & Behavioral Health

Integrations

Only Universal Health Services
Universal Health Services is classified as company. Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.